Genetically engineered animal models for in vivo target identification and validation in oncology

Methods in Molecular Biology

Volumn 986, Issue , 2013, Pages 281-305

  Texidó, Gemma ^a  

^a NONE

Author keywords

Cancer genes; Drosophila; Mouse models; Target identification in vivo; Target validation in vivo

Indexed keywords

PLASMID DNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT;

ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESEARCH; CELL DEATH; CELL PROLIFERATION; CROSS BREEDING; DNA MODIFICATION; DROSOPHILA MELANOGASTER; EMBRYONIC STEM CELL; FRUIT FLY MODEL; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HOMOLOGOUS RECOMBINATION; LOXP SITE; MOUSE MODEL; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REPORTER GENE; RETROVIRUS; TRANSGENIC ANIMAL; TRANSGENIC MOUSE; TRANSPOSON; TUMOR GENE; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; ANIMAL; ANIMAL MODEL; CANCER TRANSPLANTATION; DROSOPHILA; DRUG DESIGN; DRUG SCREENING; GENETIC ENGINEERING; GENETICS; HUMAN; METASTASIS; METHODOLOGY; MOUSE; MOUSE MUTANT; NEOPLASM; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; DROSOPHILA; DRUG DESIGN; GENETIC ENGINEERING; HUMANS; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MLCS; MLOWN;

EID: 84881251935     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-311-4_18     Document Type: Article

References (95)

1. Walker I, Newell H (2009) Do molecularly targeted agents in oncology have reduced attrition rates? Nat Rev Drug Discov 8: 15-16
2. Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell 127:679-695
3. Singh M, Johnson L (2006) Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clin Cancer Res 12:5312-5328
4. Richmond A, Su Y (2008) Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech 1:78-82
5. Heyer J, Kwong LN, Lowe SW et al (2010) Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer 10:470-480
6. Forbes SA, Bhamra G, Bamford S et al (2008) The catalogue of somatic mutations in cancer (COSMIC). Curr Protoc Hum Genet Chapter 10:Unit 10.11
7. Rago C, Vogelstein B, Bunz F (2007) Genetic knockouts and knockins in human somatic cells. Nat Protoc 2:2734-2746
8. Sandy P, Ventura A, Jacks T (2005) Mammalian RNAi: a practical guide. Biotechniques 39:215-224
9. Futami K, Kumagai E, Makino H et al (2008) Anticancer activity of RecQL1 helicase siRNA in mouse xenograft models. Cancer Sci 99:1227-1236
10. Elez R, Piiper A, Kronenberger B et al (2003) Tumor regression by combination antisense therapy against Plk1 and Bcl-2. Oncogene 22:69-80
11. Verma UN, Surabhi RM, Schmaltieg A et al (2003) Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 9:1291-1300
12. Oh BY, Lee RA, Kim KH (2011) siRNA targeting Livin decreases tumor in a xenograft model for colon cancer. World J Gastroenterol 17:2563-2571
13. Oliveira S, Storm G, Schiffelers RM (2006) Targeted delivery of siRNA. J Biomed Biotechnol 2006:63675
14. Lee-Hoeflich ST, Crocker L, Yao E et al (2008) A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 68:5878-5887
15. Barres V, Ouellet V, Lafontaine J et al (2010) An essential role for Ran GTPase in epithelial ovarian cancer cell survival. Mol Cancer 9:272
16. Sala G, Dituri F, Raimondi C et al (2008) Phospholipase Cgamma1 is required for metastasis development and progression. Cancer Res 68:10187-10196
17. Mazzoletti M, Texidó G. (2013) In vivo target validation by inducible RNAi in human xenograft mouse models, methods in molecular biology. Target identification and validation in drug discovery. Eds. Jürgen Moll and Riccardo Colombo.
18. Costantini F, Lacy E (1981) Introduction of a rabbit beta-globin gene into the mouse germ line. Nature 294:92-94
19. Hanahan D, Wagner EF, Palmiter RD (2007) The origins of oncomice: a history of thefirst transgenic mice genetically engineered to develop cancer. Genes Dev 21:2258-2270
20. Capecchi MR (1989) Altering the genome by homologous recombination. Science 244: 1288-1292
21. Taneja P, Zhu S, Maglic D et al (2011) Transgenic and knockout mice models to reveal the functions of tumor suppressor genes. Clin Med Insights Oncol 5:235-257
22. Nagy A, Gertsenstein M, Vintersten K et al (2003) Manipulating the mouse embryo-a laboratory manual. Cold Spring Harbor Laboratory Press, New York
23. Hofker MH, van Deursen J (2002) Transgenic mouse: methods and protocols, methods in molecular biology, transgenic mouse: methods and protocols, vol 209. Humana Press, New Jersey
24. Pease S, Saunders TL (2011) Advanced protocols for animal transgenesis: an ISTT manual. Springer Protocols, Springer-Verlag, Berlin, Heidelberg
25. Sauer B, Henderson N (1988) Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc Natl Acad Sci USA 85:5166-5170
26. Jackson EL, Willis N, Mercer K et al (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15:3243-3248
27. DuPage M, Dooley AL, Jacks T (2009) Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4:1064-1072
28. Zhu XD, Sadowski PD (1995) Cleavagedependent ligation by the FLP recombinase. Characterization of a mutant FLP protein with an alteration in a catalytic amino acid. J Biol Chem 270:23044-23054
29. Kwan KM (2002) Conditional alleles in mice: practical considerations for tissue-specific knockouts. Genesis 32:49-62
30. Lee CL, Moding EJ, Huang X et al (2012) Generation of primary tumors with Flp recombinase in FRT- flanked p53 mice. Dis Model Mech. doi: 10.1242/dmm.009084
31. Leone DP, Genoud S, Atanasoski S et al (2003) Tamoxifen-inducible glia-specific Cre mice for somatic mutagenesis in oligodendrocytes and Schwann cells. Mol Cell Neurosci 22:430-440
32. Hillen W, Berens C (1994) Mechanisms underlying expression of Tn10 encoded tetracycline resistance. Annu Rev Microbiol 48:345-369
33. Montoliu L (2011) Global resources: including gene trapped ES cell clones-is your gene already knocked out? In: Pease S, Saunders TL (eds) Advanced protocols for animal transgenesis. Springer Protocols, Springer-Verlag, Berlin, Heidelberg, pp 25-42
34. Schonig K, Bujard H, Gossen M (2010) The power of reversibility regulating gene activities via tetracycline-controlled transcription. Methods Enzymol 477:429-453
35. Cawthorne C, Swindell R, Stratford IJ et al (2007) Comparison of doxycycline delivery methods for Tet-inducible gene expression in a subcutaneous xenograft model. J Biomol Tech 18:120-123
36. Marks C (2009) Mouse models of human cancers consortium (MMHCC) from the NCI. Dis Model Mech 2:111
37. Uren AG, Kool J, Berns A et al (2005) Retroviral insertional mutagenesis: past, present and future. Oncogene 24:7656-7672
38. Collier LS, Carlson CM, Ravimohan S et al (2005) Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 436:272-276
39. Kool J, Berns A (2009) High-throughput insertional mutagenesis screens in mice to identify oncogenic networks. Nat Rev Cancer 9: 389-399
40. Curcio MJ, Derbyshire KM (2003) The outs and ins of transposition: from mu to kangaroo. Nat Rev Mol Cell Biol 4:865-877
41. Weiser KC, Justice MJ (2005) Cancer biology: sleeping beauty awakens. Nature 436: 184-186
42. Ivics Z, Hackett PB, Plasterk RH et al (1997) Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon fromfish, and its transposition in human cells. Cell 91:501-510
43. Ding S, Wu X, Li G et al (2005) Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell 122:473-483
44. Copeland NG, Jenkins NA (2010) Harnessing transposons for cancer gene discovery. Nat Rev Cancer 10:696-706
45. Dupuy AJ, Rogers LM, Kim J et al (2009) A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. Cancer Res 69:8150-8156
46. Yusa K, Zhou L, Li MA et al (2011) A hyperactive piggyBac transposase for mammalian applications. Proc Natl Acad Sci U S A 108:1531-1536
47. Bender AM, Collier LS, Rodriguez FJ et al (2010) Sleeping beauty-mediated somatic mutagenesis implicates CSF1 in the formation of high-grade astrocytomas. Cancer Res 70: 3557-3565
48. Coniglio SJ, Eugenin E, Dobrenis K et al (2012) Microglial stimulation of glioblastoma invasion involves EGFR and CSF-1R signaling. Mol Med. doi: 10.2119/molmed.2011.00217
49. March HN, Rust AG, Wright NA et al (2011) Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet 43:1202-1209
50. Kleinhammer A, Wurst W, Kuhn R (2011) Constitutive and conditional RNAi transgenesis in mice. Methods 53:430-436
51. Kissil JL, Walmsley MJ, Hanlon L et al (2007) Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Res 67:8089-8094
52. Meylan E, Dooley AL, Feldser DM et al (2009) Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 462:104-107
53. Xue W, Meylan E, Oliver TG et al (2011) Response and resistance to NF-kappaB inhibitors in mouse models of lung adenocarcinoma. Cancer Discov 1:236-247
54. Puyol M, Martin A, Dubus P et al (2010) A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18:63-73
55. Degrassi A, Russo M, Nanni C et al (2010) Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging. Mol Cancer Ther 9:673-681
56. Chin L, Tam A, Pomerantz J et al (1999) Essential role for oncogenic Ras in tumour maintenance. Nature 400:468-472
57. Felsher DW, Bishop JM (1999) Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4:199-207
58. Shachaf CM, Kopelman AM, Arvanitis C et al (2004) MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431:1112-1117
59. Vidal M, Cagan RL (2006) Drosophila models for cancer research. Curr Opin Genet Dev 16:10-16
60. Liu S, Leach SD (2011) Zebrafish models for cancer. Annu Rev Pathol 6:71-93
61. Kango-Singh M, Singh A (2009) Regulation of organ size: insights from the Drosophila Hippo signaling pathway. Dev Dyn 238:1627-1637
62. Staley BK, Irvine KD (2012) Hippo signaling in Drosophila: recent advances and insights. Dev Dyn 241:3-15
63. Moon RT, Bowerman B, Boutros M et al (2002) The promise and perils of Wnt signaling through beta-catenin. Science 296:1644-1646
64. Reiter LT, Potocki L, Chien S et al (2001) A systematic analysis of human disease-associated gene sequences in Drosophila melanogaster. Genome Res 11:1114-1125
65. Chien S, Reiter LT, Bier E et al (2002) Homophila: human disease gene cognates in Drosophila. Nucleic Acids Res 30:149-151
66. Caussinus E, Gonzalez C (2005) Induction of tumor growth by altered stem-cell asymmetric division in Drosophila melanogaster. Nat Genet 37:1125-1129
67. Royer C, Lu X (2011) Epithelial cell polarity: a major gatekeeper against cancer? Cell Death Differ 18:1470-1477
68. Blair SS (2003) Developmental biology: boundary lines. Nature 424:379-381
69. Brumby AM, Richardson HE (2005) Using Drosophila melanogaster to map human cancer pathways. Nat Rev Cancer 5:626-639
70. Brand AH, Perrimon N (1993) Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 118:401-415
71. Wang H, Chattopadhyay A, Li Z et al (2010) Rapid identification of heterozygous mutations in Drosophila melanogaster using genomic capture sequencing. Genome Res 20:981-988
72. Adams MD, Celniker SE, Holt RA et al (2000) The genome sequence of Drosophila melanogaster. Science 287:2185-2195
73. Boutros M, Perrimon N (2000) Drosophila genome takes flight. Nat Cell Biol 2:E53-E54
74. Carroll PM, Dougherty B, Ross-Macdonald P et al (2003) Model systems in drug discovery: chemical genetics meets genomics. Pharmacol Ther 99:183-220
75. O'Hare K, Rubin GM (1983) Structures of P transposable elements and their sites of insertion and excision in the Drosophila melanogaster genome. Cell 34:25-35
76. Rorth P (1996) A modular misexpression screen in Drosophila detecting tissue-specific phenotypes. Proc Natl Acad Sci USA 93: 12418-12422
77. Duffy JB (2002) GAL4 system in Drosophila: a fly geneticist's Swiss army knife. Genesis 34:1-15
78. Dietzl G, Chen D, Schnorrer F et al (2007) A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila. Nature 448:151-156
79. Lee T, Luo L (1999) Mosaic analysis with a repressible cell marker for studies of gene function in neuronal morphogenesis. Neuron 22: 451-461
80. Lue NF, Chasman DI, Buchman AR et al (1987) Interaction of GAL4 and GAL80 gene regulatory proteins in vitro. Mol Cell Biol 7:3446-3451
81. Willecke M, Toggweiler J, Basler K (2011) Loss of PI3K blocks cell-cycle progression in a Drosophila tumor model. Oncogene 30: 4067-4074
82. Miles WO, Dyson NJ, Walker JA (2011) Modeling tumor invasion and metastasis in Drosophila. Dis Model Mech 4:753-761
83. Gonzalez C (2007) Spindle orientation, asymmetric division and tumour suppression in Drosophila stem cells. Nat Rev Genet 8: 462-472
84. Zhou Y, Rideout WM 3rd, Zi T et al (2010) Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nat Biotechnol 28:71-78
85. Huijbers IJ, Krimpenfort P, Berns A et al (2011) Rapid validation of cancer genes in chimeras derived from established genetically engineered mouse models. Bioessays 33: 701-710
86. Isalan M (2011) Zinc-finger nucleases: how to play two good hands. Nat Methods 9:32-34
87. Miller JC, Tan S, Qiao G et al (2011) A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 29:143-148
88. McMahon MA, Rahdar M, Porteus M (2012) Gene editing: not just for translation anymore. Nat Methods 9:28-31
89. Zhang F, Cong L, Lodato S et al (2011) Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol 29:149-153
90. Hockemeyer D, Wang H, Kiani S et al (2011) Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 29: 731-734
91. Editorial (2012) Method of the year 2011. Nat Methods 9:1
92. Barker M (2012) Gene-editing nucleases. Nat Methods 9:23-26
93. Tesson L, Usal C, Menoret S et al (2011) Knockout rats generated by embryo microinjection of TALENs. Nat Biotechnol 29:695-696
94. Sander JD, Cade L, Khayter C et al (2011) Targeted gene disruption in somatic zebrafish cells using engineered TALENs. Nat Biotechnol 29:697-698
95. Weiss WA, Taylor SS, Shokat KM (2007) Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat Chem Biol 3:739-744